Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical relevance of KRAS mutations in codon 13: Where are we?

Cancer letters - 1 Feb 2014

Er Tze-Kiong, Chen Chih-Chieh, Bujanda Luis, Herreros-Villanueva Marta

Abstract excerpt

Recent advances in molecular diagnosis and the trend towards personalized medicine have made colorectal cancer one of the tumors where therapies have significantly improved patient survival after metastasis development. KRAS mutations in codon 12 and 13 are recognized biomarkers that are analyzed in clinic previously for anti-EGFR therapies administration. Since originally mutations in both codons were considered...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antibodies, Neoplasm
Share to Cetuximab

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 24051306
DOI: 10.1016/j.canlet.2013.09.012

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical relevance of KRAS mutations in codon 13: Where are we?PMID 24051306Read ↗

Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancerSemantic proximity Read ↗

KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Different oncological features of colorectal cancer codon-specific KRAS mutations: Not codon 13 but codon 12 have prognostic value.Semantic proximity Read ↗

Clinical Predictors for KRAS Codon 13 Mutations in Patients With Colorectal Cancer.Semantic proximity Read ↗

Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13.Semantic proximity Read ↗

KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer.Semantic proximity Read ↗

Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.Semantic proximity Read ↗

Prognostic Value of KRAS Mutations in Colorectal Cancer PatientsSemantic proximity Read ↗

[The role of KRAS gene mutation testing in colorectal cancer--a predictive biomarker of response to EGFR inhibitors therapy].Semantic proximity Read ↗

KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).Semantic proximity Read ↗

Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.Semantic proximity Read ↗

Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.